653
edits
(→IHC) |
(→IHC) |
||
Line 66: | Line 66: | ||
*ER -ve. | *ER -ve. | ||
*PR -ve. | *PR -ve. | ||
*often Her2 -ve | |||
Notes | Notes | ||
Line 73: | Line 74: | ||
**May respond to treatments targeting the androgen receptor<ref>{{Cite journal | last1 = Safarpour | first1 = D. | last2 = Tavassoli | first2 = FA. | title = A Targetable Androgen Receptor-Positive Breast Cancer Subtype Hidden Among the Triple-Negative Cancers. | journal = Arch Pathol Lab Med | volume = | issue = | pages = | month = Oct | year = 2014 | doi = 10.5858/arpa.2014-0122-RA | PMID = 25310144 }} | **May respond to treatments targeting the androgen receptor<ref>{{Cite journal | last1 = Safarpour | first1 = D. | last2 = Tavassoli | first2 = FA. | title = A Targetable Androgen Receptor-Positive Breast Cancer Subtype Hidden Among the Triple-Negative Cancers. | journal = Arch Pathol Lab Med | volume = | issue = | pages = | month = Oct | year = 2014 | doi = 10.5858/arpa.2014-0122-RA | PMID = 25310144 }} | ||
</ref> | </ref> | ||
**Be carefull when reading the literature in this area - is the author discussing 'molecular apocrine', 'IHC apocrine' or 'morphologic apocrine' carcinoma. Many ductal carcinomas, NOS will show AR positivity. | |||
==See also== | ==See also== |
edits